Matches in SemOpenAlex for { <https://semopenalex.org/work/W2041738951> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2041738951 endingPage "360" @default.
- W2041738951 startingPage "352" @default.
- W2041738951 abstract "Objective:To compare utilization and associated costs of epoetin alfa (EPO) and darbepoetin alfa (DARB), two erythropoiesis-stimulating agents (ESAs), in patients with cancer undergoing chemotherapy and patients with chronic kidney disease (CKD) not on dialysis in inpatient and outpatient hospital settings.Methods:An analysis of medical claims recorded between January 2006 and December 2009 was conducted using the Premier Perspective Comparative Hospital database. Patients included were ≥18 years old with cancer and chemotherapy or with pre-dialysis CKD and with ≥1 claim for EPO or DARB during a hospital inpatient or outpatient treatment episode. Patients treated with both ESAs or who were receiving dialysis were excluded. Mean cumulative drug costs and dose ratios (units EPO: mcg DARB) were calculated using cumulative dose and April 2010 wholesale acquisition costs.Results:Cancer chemotherapy: 13,832 inpatient stays (EPO: 10,454; DARB: 3378) and 5590 outpatient treatment episodes (EPO: 2856; DARB: 2734) were identified. The inpatient and outpatient populations reported ESA dose ratios of 230:1 and 238:1 with DARB cost premiums of 42% (EPO: $948; DARB: $1348) and 38% (EPO: $3358; DARB: $4627), respectively. CKD: 148,746 hospital stays (EPO: 116,017; DARB: 32,729) and 11,012 outpatient treatment episodes (EPO: 6921; DARB 4091) were identified. The inpatient and outpatient populations reported ESA dose ratios of 251:1 and 257:1 with DARB cost premiums of 30% (EPO: $566; DARB: $738) and 27% (EPO: $2077; DARB: $2642), respectively.Limitations:The lack of randomization may have led to confounding by indication. In addition, statistical significance must be interpreted with caution in studies involving large samples.Conclusions:This study of 19,422 patients with cancer receiving chemotherapy and 159,758 patients with pre-dialysis CKD reported ESA dose ratios ranging from 230:1–257:1 (units EPO: mcg DARB) and associated cost premiums of 27–42% for DARB." @default.
- W2041738951 created "2016-06-24" @default.
- W2041738951 creator A5012473008 @default.
- W2041738951 creator A5019269759 @default.
- W2041738951 creator A5024947571 @default.
- W2041738951 creator A5043332548 @default.
- W2041738951 creator A5068523311 @default.
- W2041738951 date "2012-01-01" @default.
- W2041738951 modified "2023-09-24" @default.
- W2041738951 title "Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings" @default.
- W2041738951 cites W1945929574 @default.
- W2041738951 cites W1968106809 @default.
- W2041738951 cites W1974218285 @default.
- W2041738951 cites W1983560550 @default.
- W2041738951 cites W1991038755 @default.
- W2041738951 cites W2003077486 @default.
- W2041738951 cites W2011318599 @default.
- W2041738951 cites W2048521093 @default.
- W2041738951 cites W2082382250 @default.
- W2041738951 cites W2086765462 @default.
- W2041738951 cites W2099283948 @default.
- W2041738951 cites W2112891738 @default.
- W2041738951 cites W2114265043 @default.
- W2041738951 cites W2115592617 @default.
- W2041738951 cites W2138416329 @default.
- W2041738951 cites W2146353390 @default.
- W2041738951 cites W2146789777 @default.
- W2041738951 cites W2150616882 @default.
- W2041738951 cites W2170829457 @default.
- W2041738951 cites W1995360125 @default.
- W2041738951 doi "https://doi.org/10.3111/13696998.2011.649326" @default.
- W2041738951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22168787" @default.
- W2041738951 hasPublicationYear "2012" @default.
- W2041738951 type Work @default.
- W2041738951 sameAs 2041738951 @default.
- W2041738951 citedByCount "3" @default.
- W2041738951 countsByYear W20417389512014 @default.
- W2041738951 countsByYear W20417389512017 @default.
- W2041738951 crossrefType "journal-article" @default.
- W2041738951 hasAuthorship W2041738951A5012473008 @default.
- W2041738951 hasAuthorship W2041738951A5019269759 @default.
- W2041738951 hasAuthorship W2041738951A5024947571 @default.
- W2041738951 hasAuthorship W2041738951A5043332548 @default.
- W2041738951 hasAuthorship W2041738951A5068523311 @default.
- W2041738951 hasBestOaLocation W20417389511 @default.
- W2041738951 hasConcept C126322002 @default.
- W2041738951 hasConcept C177713679 @default.
- W2041738951 hasConcept C194828623 @default.
- W2041738951 hasConcept C2776164570 @default.
- W2041738951 hasConcept C2777288759 @default.
- W2041738951 hasConcept C2778534260 @default.
- W2041738951 hasConcept C2778653478 @default.
- W2041738951 hasConcept C2779978075 @default.
- W2041738951 hasConcept C2781404941 @default.
- W2041738951 hasConcept C65409693 @default.
- W2041738951 hasConcept C71924100 @default.
- W2041738951 hasConceptScore W2041738951C126322002 @default.
- W2041738951 hasConceptScore W2041738951C177713679 @default.
- W2041738951 hasConceptScore W2041738951C194828623 @default.
- W2041738951 hasConceptScore W2041738951C2776164570 @default.
- W2041738951 hasConceptScore W2041738951C2777288759 @default.
- W2041738951 hasConceptScore W2041738951C2778534260 @default.
- W2041738951 hasConceptScore W2041738951C2778653478 @default.
- W2041738951 hasConceptScore W2041738951C2779978075 @default.
- W2041738951 hasConceptScore W2041738951C2781404941 @default.
- W2041738951 hasConceptScore W2041738951C65409693 @default.
- W2041738951 hasConceptScore W2041738951C71924100 @default.
- W2041738951 hasIssue "2" @default.
- W2041738951 hasLocation W20417389511 @default.
- W2041738951 hasLocation W20417389512 @default.
- W2041738951 hasOpenAccess W2041738951 @default.
- W2041738951 hasPrimaryLocation W20417389511 @default.
- W2041738951 hasRelatedWork W1964706798 @default.
- W2041738951 hasRelatedWork W1983560550 @default.
- W2041738951 hasRelatedWork W2009854161 @default.
- W2041738951 hasRelatedWork W2067595666 @default.
- W2041738951 hasRelatedWork W2100854655 @default.
- W2041738951 hasRelatedWork W2154211481 @default.
- W2041738951 hasRelatedWork W2618912176 @default.
- W2041738951 hasRelatedWork W2914838948 @default.
- W2041738951 hasRelatedWork W78241025 @default.
- W2041738951 hasRelatedWork W2129134611 @default.
- W2041738951 hasVolume "15" @default.
- W2041738951 isParatext "false" @default.
- W2041738951 isRetracted "false" @default.
- W2041738951 magId "2041738951" @default.
- W2041738951 workType "article" @default.